Диссертация (1154697), страница 18
Текст из файла (страница 18)
— 2016. —№11(4). — С.84-89.32.A prospective longitudinal study comparing a radical retropubicprostatectomy and permanent prostate brachytherapy regarding the health-related qualityof life for localized prostate cancer / K. Hashine, Y. Kusuhara, N. Miura, [et al.] // Jpn. J.Clin. Oncol.
— 2008. — Vol. 38. — N 7. — Р.480-485.33.localizedA prospective longitudinal survey of erectile dysfunction in patients withprostatecancertreatedwithpermanentprostatebrachytherapy/Matsushima M., Kikuchi E., Maeda T. [et al.] // J Urol. — 2013. — Vol. 189 (3). —114P. 1014-1018.34.Aluwini, S. Toxicity and quality of life after high-dose-rate brachytherapyas monotherapy for low- and intermediate-risk prostate cancer / Aluwini S., Busser W.M.,Alemayehu W.G. // Radiother Oncol. — 2015. — Vol. 117 (2). — P.252-257.35.American Brachytherapy Society consensus guidelines for high-dose-rateprostate brachytherapy / Yamada Y., Rogers L., Demanes D.
J. [et al.] //Brachytherahy — 2012. — Vol. 11(1) — Р. 20–32.36.American Brachytherapy Society consensus guidelines for transrectalultrasound-guided permanent prostate brachytherapy / Davis BJ., Horwitz EM., Lee WR.[et al.] // Brachytherapy. — 2012. — Vol. 11 (1).
— P. 6–19.37.An MRI-based dose--reponse analysis of urinary sphincter dose and urinarymorbidity after brachytherapy for prostate cancer in a phase II prospective trial / RegisterSP, Kudchadker RJ, Levy LB. [et al.] // Brachytherapy. — 2013. — Vol.12. — №3. —P.210-216.38.Application of neoadjuvant hormonal therapy in (125)I permanent seedimplantation for prostate cancer / Cui X, Li Q, Xu JJ. [et al.] // Zhonghua Yi Xue Za Zhi.— 2012. — Vol.16. — 92(38). — P.2710-2712.39.Association between long-term erectile dysfunction and biochemicalrecurrence after permanent seed I(125) implant brachytherapy for prostate cancer. Alongitudinal study of a single-institution / Morgia G., Castelli T., Privitera S. [et al.] //Aging Male. — 2016.
— Vol.19. — №1. — Р.15-19.40.Ballek, N.K. Reconstruction of radiationinduced injuries of the lower urinarytract / Ballek N.K., Gonzalez C.M. // Urologic Clinics of North America. — 2013. —Vol.40 (3). — P.407–419.41.Barringer, B.S. Radium in the treatment of prostatic carcinoma /B.S. Barringer // Ann.
Surg. — 1924. — Vol. 80. — N 6. — Р. 881-884.42.Boehm, K. Five-year biochemical recurrence-free and overall survivalfollowing high-dose-rate brachytherapy with additional external beam or radicalprostatectomy in patients with clinically localized prostate cancer / Boehm K.,Schiffmann J, Tian Z. // Urol Oncol.
— 2016. — 34(3). — P.119.11543.Cancer incidence and mortality worldwide: Sources, methods and majorpatterns in GLOBOCAN 2012 / Ferlay Q., Soerjomataram I. [et al.] // InternationalJournal of Cancer. — 2015. – Vol. 136(5). – P. 359-386.44.Challenges in MR-only seed localization for postimplant dosimetry inpermanent prostate brachytherapy / Zijlstra F., Moerland M.A., van der Voort vanZyp J.R.N., Noteboom J.L. [et al.] // Med. Phys. — 2017. – Vol.44(10). – P.5051-5060.45.Chen, M.L.
Urethral Strictures and Stenoses Caused by Prostate Therapy /Chen M.L., Correa A.F., Santucci RA. // Reviews in Urology. — 2016. – Vol. 18(2). –P.90-102.46.Chira, C. Prostate volume changes during permanent seed brachytherapy: ananalysis of intra-operative variations, predictive factors and clinical implication / ChiraC, Delouya G, Larrivée S. // Radiat Oncol. — 2013. — Vol.9; 8. — P.177.47.Clinical outcomes of 125I brachytherapy with and without external-beamradiation therapy for localized prostate cancer: results from 300 patients at a singleinstitution in Japan / Maki S., Itoh Y., Kubota S., Okada T. [et al.] // Journal of RadiationResearch.
— 2017. – Vol. 58(6). – P. 870–880.48.Clinical outcomes of patients with localized and locally advanced prostatecancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at ourinstitute / Makino T., Mizokami A., Namiki M. [et al.] // Anticancer Research. —2015. — Vol. 35(3).
— P. 1723-1728.49.Contreras, J.A. Quality of life after high-dose-rate brachytherapymonotherapy for prostate cancer / Contreras J.A, Wilder R.B., Mellon E.A. // Int. Braz.J. Urol. — 2015. — 41(1). — Р. 5-40.50.Conventional versus automated implantation of loose seeds in prostatebrachytherapy: analysis of dosimetric and clinical results / Genebes C., Filleron T., GraffP., Jonca F.
[et al.] // International Jornal of Radiation Oncology Biology Physics. —2013. – Vol. 87(4). – P. 651-658.51.Corticosteroid use after prostate brachytherapy reduces the risk of acuteurinary retention / D.E. Sacco, M. Daller, J.A. Grocela [et al.] // BJU Int. — 2003. —Vol. 91. — N 4. — P. 345-349.11652.Cosset, J.M. Permanent implant prostate cancer brachytherapy: 2013 state-of-the art / Cosset J.M., Hannoun-Lévi J.M., Peiffert D.
// Cancer Radiother. — 2013. —Vol. 17 (2). — P.111-117.53.Decline in acute urinary toxicity: a long-term study in 2011 patients withprostate brachytherapy within a provincial institution / Chan E.K., Keyes M., Pickles T.[et al.] // Brachytherapy. — 2014. — Vol.13 (1). — P. 46-52.54.Demanes, D.J. High-dose-rate brachytherapy as monotherapy for prostatecancer / Demanes D.J., Ghilezan M.I. // Brachytherapy.
— 2014. — Vol.13 (6). — P. 529541.55.Dindo, D. Classification of surgical complications: A new proposal withevaluation in a cohort of 6336 patients and results of a survey / Dindo D., Demartines N.,Clavien P.A. // Ann Surg. — 2004. — Vol. 240. — P. 205–213.56.Does neoadjuvant hormonal therapy improve urinary function when given tomen with very large prostates undergoing prostate brachytherapy? / Stone N.N., MarshallD.T., Stone J.J.
[et al.] // J. Urol. – 2010. - Vol. 183. - N 2. - P. 634-639.57.Does supplemental external beam radiation therapy impact urinary, bowel,and erectile function following permanent prostate brachytherapy?: results of twoprospective randomized trials / Merrick G.S., Tennant A., Wallner K.E., Galbreath R. [etal.] // J. Contemp. Brachytherapy. — 2017. – Vol.9(5). – P.403-409.58.Early quality of life outcomes in patients with prostate cancer managed byhigh-dose-rate brachytherapy as monotherapy / Komiya A., Fujiuchi Y., Ito T.,Morii A. // Int J Urol. — 2013. — Vol.
20 (2). — P. 185-192.59.Effect of transurethral resection on urinary quality of life after permanentprostate brachytherapy / G.S. Merrick, W.M. Butler, K.E. Wallner, R.W. Galbreath // I. J.Radiation Oncology. — 2004. —Vol. 58. — N 1. — P. 81-88.60.Efficacy of holmium laser urethrotomy and intralesional injection of SantoshPGI tetra-inject (Triamcinolone, Mitomycin C, Hyaluronidase and N-acetyl cysteine) onthe outcome of urethral strictures / Kumar S., Kishore L., Sharma A.P. [et al.] // CentEuropean J.
Urol. — 2015. — Vol.68 (4). — P.462-465.61.Endoscopie re-establishment of urethral continuity after traumatic disruption117of the membranous urethra / Gonzales R., Chiou R.K., Hekmat K., Fraley E.E. // J.Urol. — 1983. — Vol. 130. — P. 785.62.Erectile function following brachytherapy, external beam radiotherapy, orradical prostatectomy in prostate cancer patients / Putora P.M., Engeler D., Haile S.R.[et al.] // Strahlenther Onkol. — 2016.
— Vol.192 — №3. — P.182-189.63.Evaluation of continence following 532 nm laser prostatectomy for patientspreviously treated with radiation therapy or brachytherapy / No D., Osterberg E.C.,Otto B. [et al.] // Lasers Surg Med. — 2013. — Vol.6.
— P.358-361.64.Five-year outcomes after iodine-125 seed brachytherapy for low-riskprostate cancer at three cancer centres in the UK / Dickinson P.D., Malik J., Mandall P.[et al.] // BJU Int. — 2014. — Vol.113 (5). — P.748-753.65.Five-year potency preservation after iodine-125 prostate brachytherapy /Nishimura S., Yorozu A., Ohashi T. [et al.] // Int J Clin Oncol. — 2014. — Vol.19.
—№5. — P.940-945.66.GEC/ESTROrecommendationsonhighdoserateafterloadingbrachytherapy for localized prostate cancer: An update / Hoskin P.J., Colombo A., HenryA. [et al.] // Radiother Oncol. — 2013. — 107. — Р. 32–325.67.Guarneri, A. 125I brachytherapy for localized prostate cancer: a singleinstitution experience / Guarneri A., Botticella A., Filippi A.R. // Tumori. — 2013. —Vol.99 (1). — P.83-87.68.Hennequin, C. Prostate brachytherapy: indications and outcomes /Hennequin C., Cormier L., Richaud P. // Prog Urol.
— 2013. — Vol.23 (6). — P.378385.69.Highdoserate interstitial brachytherapy as monotherapy for clinicallylocalized prostate cancer: treatment evolution and mature results / Zamboglou N.,Tselis N., Baltas D., [et al.] // Int J Radiat Oncol Biol Phys. — 2013. — Vol.85 (3). —P.672-678.70.Hindson, B.R.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
